Skip to content

Long-acting cabotegravir injection shows promise for HIV prevention

Raphael Landovitz at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Doravirine combination pill looks good for initial HIV treatment

Kathleen Squires at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

Dzintars Gotham presenting at IAS 2017. Image credit: Enzo Poultreniez / http://aides.org

Medical male circumcision for HIV has benefits for women too

Carlos Toledo presenting at IAS 2017. Photo by Roger Pebody, aidsmap.com

Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa

Katherine Gill presenting at IAS 2017. Photo by Roger Pebody, aidsmap.com

Ipergay trial: PrEP still protected people who had less sex and used it less often

Guillemette Antoni at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Another HIV vaccine efficacy trial will start this year

Hanneke Schuitemaker at IAS 2017. Photo by Gus Cairns, aidsmap.com

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

Karine Lacombe at IAS 2017. Photo by Steve Forrest/Workers' Photos/IAS